A Decade of NIH Cardio-Oncology Research Collaboration: Continued Funding Opportunities

Cancer treatment-related cardiotoxicity is a leading cause of treatment-associated morbidity and mortality in cancer survivors. The gaps in knowledge related to cardiotoxicity are large, including mechanisms of cardiac injury, clinical risk prediction, screening, prevention, and treatment, as well as the similarities and differences between cancer induced cardiotoxicity and primary cardiovascular disease. This webinar – co-sponsored by the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI) – will highlight the contributions of the NIH Cancer Treatment-related Cardiotoxicity Initiative to addressing gaps and on-going efforts to support cardio-oncology research.

Speakers

Bishow Adhikari, Ph.D. - NHLBI, Division of Cardiovascular Sciences

Patrice Desvigne-Nickens, M.D. - NHLBI, Division of Cardiovascular Sciences

Eileen Dimond, R.N., M.S. - NCI, Division of Cancer Prevention

Lori Minasian, M.D., F.A.C.P. - NCI, Division of Cancer Prevention

Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N. - NCI, Division of Cancer Control and Population Sciences

Scarlet Shi, Ph.D. - NHLBI, Division of Cardiovascular Sciences

Denise Wiesch, M.P.H., Ph.D. - NIH Center for Scientific Review

Co-Sponsors

NCI & NHLBI

Intended Audience

Researchers, advocates, policymakers, health care professionals, and those with an interest in cardio-oncology.

Slides

• A Decade of NIH Cardio-Oncology Research Collaboration: Continued Funding Opportunities
• The Peer Review Process